GEP19991639B - DNA-Sequence, Cell, Vector, Polypeptide, Method for Obtaining and Pharmaceutical Formulation - Google Patents
DNA-Sequence, Cell, Vector, Polypeptide, Method for Obtaining and Pharmaceutical FormulationInfo
- Publication number
- GEP19991639B GEP19991639B GEAP1993984A GEAP1993000984A GEP19991639B GE P19991639 B GEP19991639 B GE P19991639B GE AP1993984 A GEAP1993984 A GE AP1993984A GE AP1993000984 A GEAP1993000984 A GE AP1993000984A GE P19991639 B GEP19991639 B GE P19991639B
- Authority
- GE
- Georgia
- Prior art keywords
- epo
- polypeptides
- dna sequences
- dna
- polypeptide
- Prior art date
Links
- 108091028043 Nucleic acid sequence Proteins 0.000 title abstract 4
- 229920001184 polypeptide Polymers 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 241000282693 Cercopithecidae Species 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 239000002299 complementary DNA Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 239000006166 lysate Substances 0.000 abstract 1
- 239000013600 plasmid vector Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 abstract 1
- 230000003362 replicative effect Effects 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65584184A | 1984-09-28 | 1984-09-28 | |
| US06/675,298 US4703008A (en) | 1983-12-13 | 1984-11-30 | DNA sequences encoding erythropoietin |
| UA3917560A UA54363C2 (uk) | 1984-09-28 | 1985-06-19 | Виділена молекула днк, яка кодує людський еритропоетин (варіанти), біологічно функціональний кільцевий плазмідний або вірусний днк-вектор, штам еукаріотичних клітин-хазяїв (варіанти), спосіб одержання поліпептиду, фармацевтична композиція |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEP19991639B true GEP19991639B (en) | 1999-03-23 |
Family
ID=27097052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP1993984A GEP19991639B (en) | 1984-09-28 | 1993-07-09 | DNA-Sequence, Cell, Vector, Polypeptide, Method for Obtaining and Pharmaceutical Formulation |
Country Status (9)
| Country | Link |
|---|---|
| CN (1) | CN1016795B (OSRAM) |
| CZ (1) | CZ281542B6 (OSRAM) |
| FI (1) | FI93470C (OSRAM) |
| GE (1) | GEP19991639B (OSRAM) |
| GR (1) | GR852245B (OSRAM) |
| HU (1) | HU204889B (OSRAM) |
| NO (1) | NO852384L (OSRAM) |
| PT (1) | PT81213B (OSRAM) |
| SK (1) | SK443885A3 (OSRAM) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106608906A (zh) * | 2015-10-22 | 2017-05-03 | 天津药物研究院有限公司 | 一种具有刺激红细胞生成功能的环形多肽的制备及其应用 |
-
1985
- 1985-06-13 NO NO852384A patent/NO852384L/no unknown
- 1985-06-14 FI FI852377A patent/FI93470C/fi not_active IP Right Cessation
- 1985-06-18 SK SK4438-85A patent/SK443885A3/sk unknown
- 1985-06-18 CZ CS854438A patent/CZ281542B6/cs not_active IP Right Cessation
- 1985-06-18 HU HU852404A patent/HU204889B/hu unknown
- 1985-06-19 CN CN85106191A patent/CN1016795B/zh not_active Expired
- 1985-09-16 GR GR852245A patent/GR852245B/el unknown
- 1985-09-27 PT PT81213A patent/PT81213B/pt unknown
-
1993
- 1993-07-09 GE GEAP1993984A patent/GEP19991639B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SK279959B6 (sk) | 1999-06-11 |
| HU204889B (en) | 1992-02-28 |
| SK443885A3 (en) | 1999-06-11 |
| NO852384L (no) | 1986-04-01 |
| GR852245B (OSRAM) | 1986-01-17 |
| CN85106191A (zh) | 1987-07-29 |
| FI93470B (fi) | 1994-12-30 |
| CZ443885A3 (en) | 1996-09-11 |
| FI852377L (fi) | 1986-03-29 |
| PT81213A (en) | 1985-10-01 |
| FI93470C (fi) | 1995-04-10 |
| CN1016795B (zh) | 1992-05-27 |
| CZ281542B6 (cs) | 1996-11-13 |
| HUT40694A (en) | 1987-01-28 |
| PT81213B (pt) | 1987-09-30 |
| FI852377A0 (fi) | 1985-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20032250L (no) | Anvendelse av et hpG-CSF-polypeptid til fremstilling av et medikament for åstanse proliferasjon av leukemiceller | |
| ES8802329A1 (es) | Un procedimiento para preparar un polipetido que tiene en parte o en su totalidad la conformacion estructural primaria de la critropoyetina de origen natural. | |
| CZ738982A3 (en) | Human immune interferon and derivative thereof, separated dna with sequence encoding human immune interferon, recombinant cloning vector, replicable expression vector, recombinant micro-organism or cellular culture, pharmaceutical preparation, process for preparing the human immune interferon and its use | |
| AU2790292A (en) | Viral recombinant vectors for expression in muscle cells | |
| WO1995006743A3 (en) | Methods and compositions for the large scale production of recombinant adeno-associated virus | |
| BG60250B1 (bg) | Метод за получаване на тумор некрозис фактор | |
| NZ218332A (en) | Il-4(interleukin-4), recombinant production, dna, vectors and pharmaceutical composition | |
| EP0275204A3 (en) | Production of fibroblast growth factor | |
| EP0111814A3 (en) | The cloning and expression of nucleotide sequences encoding bovine growth hormone | |
| EP2145961A3 (en) | Porcine adenovirus type 3 genome | |
| CA2083396A1 (en) | Derivatives of human bile-salt stimulated lipase, and pharmaceutical compositions containing them | |
| HUP9800520A2 (hu) | Génexpresszió emlős sejtekben | |
| HIRSCHBERG et al. | Stimulation of human lymphocytes by cultured allogeneic skin and endothelial cells in vitro | |
| FI852377L (fi) | Menetelmä erytropoietiinin valmistamiseksi ja siinä käytettyjä DNA-sekvenssejä | |
| AU5276296A (en) | Medicament containing at least one part of the ul84 protein of the cytomegalovirus, use of polypeptides corresponding to the amino acid sequence of the ul84 protein, and process for introducing ul84 into target cells | |
| Štambuk et al. | Immune response and clinical findings in uveitis, optic neuritis and multiple sclerosis during Peptid-M (Lupex) therapy | |
| DK200301685A (da) | Isoleret polypeptid med hæmatopoietiske biologiske egenskaber som naturligt forekommende hpG-CSF, DNA-sekvens kodende for denne, plasmider indeholdende sekvensen, hermed transformerede/transficerede værtsceller, | |
| JPS6447393A (en) | Novel physiologically active polypeptide |